cilostazol has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bajaj, M; Birnbaum, Y; Castillo, AC; Ling, S; Perez-Polo, JR; Qian, J; Ye, H; Ye, Y | 1 |
1 review(s) available for cilostazol and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for cilostazol and exenatide
| Article | Year |
|---|---|
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Activation; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Isoquinolines; Lipoxins; Male; Mice; Myocardial Infarction; Myocardium; Peptides; Phosphodiesterase 3 Inhibitors; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Receptors, Glucagon; Signal Transduction; Sulfonamides; Tetrazoles; Triglycerides; Up-Regulation; Venoms | 2013 |